RANI (Rani Therapeutics Holdings) 3-Year Sortino Ratio: 0.86 (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.81
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings 3-Year Sortino Ratio?

Rani Therapeutics Holdings RANI -3.74% 32 3-Year Sortino Ratio is 0.86 as of Sep. 15, 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

The 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. As of today (2026-09-15), Rani Therapeutics Holdings's 3-Year Sortino Ratio is 0.86.

Rani Therapeutics Holdings  (NAS:RANI) 3-Year Sortino Ratio Explanation

The 3-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past three year. It is calculated as the annualized result of the average three-year monthly excess returns divided by the standard deviation of negative returns in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.

Rani Therapeutics Holdings 3-Year Sortino Ratio Related Terms

RANI vs CGTX, VRCA, YARW: 3-Year Sortino Ratio Comparison

For the Biotechnology subindustry, Rani Therapeutics Holdings's 3-Year Sortino Ratio, along with its competitors' market caps and 3-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rani Therapeutics Holdings 3-Year Sortino Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's 3-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's 3-Year Sortino Ratio falls into.


RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
3-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings 3-Year Sortino Ratio Calculation

The 3-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last three year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 3-Year Sortino Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past three year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Frequently Asked Questions Learn more about 3-Year Sortino Ratio →
What does a 3-Year Sortino Ratio of 0.86 mean?
Rani Therapeutics Holdings (RANI) has a 3-Year Sortino Ratio of 0.86 as of Sep. 15, 2026. 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. View historical data for Rani Therapeutics Holdings and its competitors.
Is Rani Therapeutics Holdings' 3-Year Sortino Ratio too high?
Rani Therapeutics Holdings' current 3-Year Sortino Ratio is 0.86. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' 3-Year Sortino Ratio compare to CGTX and VRCA?
Rani Therapeutics Holdings' 3-Year Sortino Ratio of 0.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Sortino Ratio for a Biotechnology company?
A good 3-Year Sortino Ratio depends on the Biotechnology industry context. However, 3-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Sortino Ratio mean?
A high 3-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. View historical data for Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current 3-Year Sortino Ratio is 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current 3-Year Sortino Ratio of 0.86. The current 3-Year Sortino Ratio is 0.86. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Sortino Ratio calculated?
3-Year Sortino Ratio is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current 3-Year Sortino Ratio is 0.86 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

3-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price